Induction with infliximab and a plant-based diet as first-line (IPF) therapy for moderate-to-severe to severe ulcerative colitis

被引：0
|
作者：
Chiba, Mitsuro [1 ]
Nakane, Kunio [1 ]
Tsuji, Tsuyotoshi [1 ]
Tsuda, Satoko [1 ]
Ishii, Hajime [1 ]
Ohno, Hideo [1 ]
Watanabe, Kenta [1 ]
Ito, Mai [1 ]
Obara, Yu [1 ]
Komatsu, Masafumi [1 ]
Sugawara, Takeshi [2 ]
机构：
[1] Akita City Hosp, Dept Internal Med GI Hepatol, Akita, Japan
[2] Nakadori Gen Hosp, Dept Internal Med GI Hepatol, Akita, Japan
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2018年 / 33卷
关键词：
ulcerative colitis; infliximab; plant-based diet; remission; inflammatory bowel disease;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OE-0103 (P
引用
收藏
页码：483 / 483
页数：1
相关论文
共 50 条
  • [1] promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy
    Naganuma, Makoto
    [J]. JOURNAL OF GASTROENTEROLOGY, 2024, 59 (07) : 643 - 643
  • [2] Promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy
    Chiba, Mitsuro
    Kimura, Kazuya
    [J]. JOURNAL OF GASTROENTEROLOGY, 2024, 59 (07) : 641 - 642
  • [3] Infliximab and Plant-Based Diet as First-Line Therapy Followed by Corticosteroid Therapy for Severe Ulcerative Colitis: A Case Report
    Chiba, Mitsuro
    Tsuji, Tsuyotoshi
    Masai, Rie
    Odashima, Masaru
    Sageshima, Masato
    [J]. GASTROINTESTINAL DISORDERS, 2022, 4 (04): : 230 - 236
  • [4] Appendiceal Orifice Inflammation in Severe Ulcerative Colitis and Its Resolution With Infliximab and Plant-based Diet as First-line Therapy
    Chiba, Mitsuro
    Ishii, Hajime
    Sageshima, Masato
    Iwabuchi, Akira
    [J]. INFLAMMATORY BOWEL DISEASES, 2021, 27 (11) : E138 - E139
  • [5] Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
    Yokomizo, Lauren
    Limketkai, Berkeley
    Park, K. T.
    [J]. BMJ OPEN GASTROENTEROLOGY, 2016, 3 (01):
  • [6] COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS
    Beilman, Candace L.
    Fedorak, Richard N.
    Halloran, Brendan P.
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S260 - S261
  • [7] The Pharmacokinetics of Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
    Brandse, Johannan F.
    van der Kleij, Desiree
    Wolbink, Gert-Jan
    Rigter, Irma M.
    Baars, Paul A.
    Lowenberg, M.
    Ponsioen, Cyriel
    Jansen, Jeroen M.
    van den Brink, Gijs R.
    Mathot, Ron A.
    D'Haens, Geert R.
    [J]. GASTROENTEROLOGY, 2014, 146 (05) : S134 - S134
  • [8] Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis
    Hyams, Jeffrey
    Damaraju, Lakshmi
    Blank, Marion
    Johanns, Jewel
    Guzzo, Cynthia
    Winter, Harland S.
    Kugathasan, Subra
    Cohen, Stanley
    Markowitz, James
    Escher, Johanna C.
    Veereman-Wauters, Gigi
    Crandall, Wallace
    Baldassano, Robert
    Griffiths, Anne
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (04) : 391 - U169
  • [9] First Oral Drug for Moderate-To-Severe Ulcerative Colitis
    Aschenbrenner, Diane S.
    [J]. AMERICAN JOURNAL OF NURSING, 2018, 118 (09) : 22 - 22
  • [10] Etrolizumab in moderate-to-severe ulcerative colitis
    Armuzzi, Alessandro
    Felice, Carla
    [J]. LANCET, 2014, 384 (9940): : 285 - 286
12345